Alberto Bernareggi

Title: Alberto Bernareggi: Innovator in Cardiovascular Treatments

Introduction

Alberto Bernareggi is a notable inventor based in Cernobbio, Italy. He has made significant contributions to the field of cardiovascular medicine through his innovative research and development of new therapeutic agents. His work focuses on improving treatment options for patients with heart conditions.

Latest Patents

Bernareggi holds a patent for "Piperidine urea derivatives for use as inotropic agents." This invention concerns the use of specific compounds represented by formula (I) as inotropic agents. The compounds, including 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, exhibit significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models. This makes them particularly useful for treating cardiovascular patients. Unlike known inotropic agents, these compounds enhance cardiomyocyte contractility without affecting calcium mobilization, thus avoiding adverse effects associated with increased calcium concentrations.

Career Highlights

Throughout his career, Bernareggi has worked with prominent companies in the healthcare sector, including Helsinn Healthcare and Anacardio AB. His expertise in developing innovative treatments has positioned him as a valuable contributor to advancements in cardiovascular therapies.

Collaborations

Bernareggi has collaborated with notable professionals in his field, including Lars Lund and Emanuela Lovati. These partnerships have further enriched his research and development efforts.

Conclusion

Alberto Bernareggi's contributions to cardiovascular medicine through his innovative patent demonstrate his commitment to improving patient care. His work continues to pave the way for safer and more effective treatment options for individuals with heart conditions.